Get the Stockscreener App
3.95
2.96%
-0.10
C 4 Therapeutics Inc stock is traded at $3.95, with a volume of 90,082.
It is down -2.96% in the last 24 hours and down -37.12% over the past month.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
See More
Previous Close:
$4.05
Open:
$4.03
24h Volume:
90,082
Relative Volume:
0.09
Market Cap:
$283.06M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-1.386
EPS:
-2.85
Net Cash Flow:
$-108.55M
1W Performance:
-16.74%
1M Performance:
-37.12%
6M Performance:
-31.77%
1Y Performance:
+165.54%
1-Day Range:
$3.89
$4.085
1-Week Range:
$3.84
$4.9298
52-Week Range:
$1.06
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CCCC | 3.95 | 283.06M | 20.76M | -132.49M | -108.55M | -2.85 |
| VRTX | 446.39 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 584.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.09 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.30 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
C4 Therapeutics appoints Steve Hoerter to board - Investing.com
C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com UK
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Bakersfield Californian
C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan
C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha
CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times
C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times
C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Will C4 Therapeutics' Upcoming Multiple Myeloma And NHL Trial Results Drive Stock Recovery? - RTTNews
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN
C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35 - GuruFocus.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):